Marco Sanduzzi Zamparelli

Trial design is an evolving issue in which statisticians should be involved from time zero. Expert knowledge in all dimensions is key

The next Talk Liver to Me podcast drops tomorrow!! Here's a sneak-peek from this interactive discussion between @MattiasMandorf1, @MarcoSanduzzi and @LorenzaRimassa! Read more: easl.eu/event/updated-… #LiverTwitter #LiverX

Present at #ILCA26 & share your latest research, receive feedback, spark new collaborations and most importantly contribute to the advancement of liver cancer care and research. ➡️Get started and submit before 13 April 2026: shorturl.at/eDxXr @QingheZeng @Valeriechew29

The call for abstracts is officially open for the ILCA Annual Conference and this is your moment to be where the science meets clinical practice. Read more about the topics and submit your abstract before 13 April 2026: shorturl.at/fOtLI @docamitgs

Results of the GOING investigator initiated trial for 2nd line in HCC are already on-line. We tested a sequential add-on strategy rather than two drugs from star. Encouraging response rate while preserving safety. pubmed.ncbi.nlm.nih.gov/41725391/ @hospitalclinic @idibaps @ContraCancerEs

Here the link to the BCLC 2025 model authors.elsevier.com/c/1mZTWcOnAYVAl. The CUSE approach informs options to consider according to strength of evidence. Individualized decision making with patient involvement. @hospitalclinic @ILCAnews @ContraCancerEs @EASLnews

Great informative talk by @MarcoSanduzzi about future prospects of systemic treatment for HCC at the @AEEHLiver PGC. Experience + knowledge @hospitalclinic @idibaps @ContraCancerEs

If you haven't heard yet, the ILCA Annual Conference is coming back to Europe this year and we’ll meet in Brussels, 3-5 Sept. ! Keep an eye out for more updates and the #ILCA26 abstract submission opening soon. shorturl.at/FtDeV For now, let’s look back at #ILCA25 📸

It’s official – #ILCA26 is returning to Europe! Join us in Brussels, Belgium, on 3–5 September 2026 for three days of insights into the latest in #livercancer research. @StephenLChan1 @docamitgs @Valeriechew29 @LorenzaRimassa @AnjanaPillaiMD @siadaniela @allaire_manon

A webinar to comment the Lancet Commission paper about liver cancer takes place on Thursday. We will comment geographic differences to be solved in order to secure access to effective treatments, as well as research challenges to be tackled . link hubs.li/Q03GK-R30

Recent advances in liver cancer treatment have brought new hope to patients worldwide. But progress is also about making care more personal with tailored treatment approaches that match each patient’s unique needs. 💚 #LiverCancerAwarenessMonth

Representación del Comité Multidisciplinar de Cáncer de Hígado de @HUCA_Asturias en BCLC UPDATE by @BCLC_group Volvemos cargados de energía e ilusión. Gracias @ma5RN por tu excelente organización ❤️❤️ Nos vemos en 2026!!!!

🆕The Hepatic Oncology Research Group @BCLC_group has published the new version of the guidelines for the management of hepatocellular carcinoma, the most common primary liver cancer These guidelines present a new model for personalizing treatment 👉f.mtr.cool/jqnvvgewpi

The BCLC 2025 model for prognosis and treatment recommendation is available in press. journal-of-hepatology.eu/article/S0168-… In brief, it will be presented by @ma5RN with introduction of the CUSE concept #about" target="_blank" rel="nofollow noopener">bclccuse.ai/#about Major relevance for clinical decision making @hospitalclinic

The presentation takes place. Full room!!

The BCLC 2025 update starts next Monday. We will have full room but virtual attendance is available. Worth to see the launch of the updated BCLC prognostic and treatment model for HCC @hospitalclinic @AEEHLiver @ILCAnews @EASLnews @AASLDtweets @ContraCancerEs @idibaps

Nice involvement of @MarcoSanduzzi at the @aeeh translational meeting in Pamplona. Great recruit into the BCLC! @hospitalclinic @idibaps @ContraCancerEs

@SilviaAffo @AEEHLiver @ContraCancerEs @FundacionFero @atuvibi Mesa redonda sobre la “Participación ciudadana en la Investigación.” 📍Informar y educar a los pacientes y a la sociedad 📍Visibilizar el cáncer de hígado 📍Involucrar a los pacientes en el diseño de los estudios y en la evaluación de los proyectos

🧬 The #EASLMTB panel discusses the case presented by @MarcoSanduzzi and moderated by @ma5RN. ☢️ Here are some radiology key points highlighted by @VChernyakMD: • No good response criteria to immunotherapy in clinical practice (mRECIST or iRECIST for clinical trials/research) • NET and HCC have overlapping imaging features (APHE; +/- WO) • Based on imaging, no clues to suggest histologic conversion, only change in response @EASLnews @siadaniela @Vaital73 #EASLMTB #LiverX

🩺 Clinical case preview - tonight’s #EASLMTB! A 75-year-old male with HCV-related cirrhosis and a new 57 mm sVIII nodule with vascular invasion. 👉 Diagnosis: hepatocellular carcinoma. How will he respond to treatment? What will happen next? 🚨 Register and join the experts' discussion in 30 minutes! easl-eu.zoom.us/webinar/regist… @EASLnews @MarcoSanduzzi @VChernyakMD @siadaniela @Vaital73 #EASLMTB #LiverX